Kathleen Danenberg, Peter Danenberg and Steven Swenson from the Keck School of Medicine of USC founded Response Genetics to leverage breakthrough, patented technology from USC for the extraction of genetic information from formalin-fixed, paraffin-embedded clinical trial samples. Now a publicly traded company (NASDAQ: RGDX), Response Genetics’ success in developing this technology has led to the development of more customized and targeted patient therapies known as “personalized medicine.”